Posted by Michael Wonder on 21 Aug 2020
Decision on schedule changes made in response to COVID-19
21 August 2020 - Earlier this year, PHARMAC amended or removed funding criteria for many pharmaceuticals in order to help improve access to these treatments in anticipation of and/or response to COVID-19 impacts on the health sector as a result of shifting to Alert Level 4 in March.
PHARMAC is now able to announce the longer-term funding arrangements for these pharmaceuticals.
For some, this means that the previous criteria will be reinstated; for others, these temporary arrangements will become permanent.
